You are here

Structural & Congenital Heart Disease


Patients who received a mechanical prosthesis for surgical replacement of aortic or mitral valves derived a significant long-term survival benefit versus those who received a biologic prosthesis, according to a study in the New England Journal of Medicine.

Nearly half of all valve hospitals in the U.S. are misclassified as either low- or high-performing, according to research published in JAMA Cardiology—but that problem might have a simple fix.

DENVER — Transcatheter aortic valve replacement (TAVR) is an “economically dominant” strategy compared to surgical aortic valve replacement (SAVR) for patients with aortic stenosis at intermediate surgical risk, according to data presented by David J. Cohen, MD, MSc, Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Research examining 278 patients with in-stent restenosis (ISR) found that drug-eluting balloon (DEB) was non-inferior in comparison with drug-eluting stent (DES) in terms of six-month minimal lumen diameter (MLD).

DENVER — Measuring frailty could lead to more accurate predictions of outcomes following transcatheter aortic valve replacement (TAVR) than a validated risk algorithm, according to research presented Oct. 30 at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.


Recent Headlines

Transcatheter closure may be alternative solution of aortic anastomosis leak

An aortic anastomosis leak (AAL) is a complication that’s difficult to address after surgery, but a case study from Chinese researchers offers a possible alternative to the usual method of handling this challenging issue—which is to operate.

BAV boasts 70% success rate in patients with congenital aortic stenosis

Balloon aortic valvuloplasty (BAV), the most common treatment for isolated congenital aortic stenosis (AS), demonstrated a 70 percent success rate in a study of more than 1,000 patients.

Prevention takes on new meaning with embryos, and predicting frailty in the elderly

U.S. scientists in July edited the DNA of a human embryo. It’s a first, it’s just the beginning and could someday mean the end of children born with hypertrophic cardiomyopathy. Imagine wiping out sudden cardiac death in young athletes someday.  

MR reduction after TMVR with the FORTIS valve maintained at 2 years

The first report to address long-term outcomes for patients with severe native mitral regurgitation (MR) who are treated with transcatheter mitral valve replacement has found that post-procedural reductions in MR held up over time, with no significant recurrence upon two-year follow-up.

Researchers: Off-label TAVRs yield ‘acceptable results’

Patients receiving off-label transcatheter aortic valve replacement (TAVR) are more likely to suffer adverse outcomes than other TAVR patients, according to new research. However, risk-adjusted mortality is similar between the two groups at one year post-procedure.

TAVR, SAVR produce similar long-term health gains

For patients with severe aortic stenosis (AS) at intermediate surgical risk, transcatheter aortic valve replacement (TAVR)—especially the transfemoral approach—might be a good solution.

TAVI utilization rate highest Northeast US; mortality highest in South

Transcatheter aortic valve implantation (TAVI) has skyrocketed in the United States, jumping from 24.8 implants per million adults in 2012 to 63.2 in 2014. A recent study examined regional differences in mortality, utilization and healthcare resource use.

Birth weight strongly predictive of survival in infants with congenital heart disease

Infants with congenital heart disease (CHD) born post-term and with the most body weight have the best chance of surviving for five years, while lighter, preterm babies have poorer chances, according to new research.

Study: All Portico heart valve sizes demonstrate effective short-term performance

All sizes of the Portico TAVR system resulted in effective and safe short-term treatment of high-risk patients, according to a new study.

Risk of stroke in AFib patients associated with aortic curvature

Atrial fibrillation (AFib) heightens stroke risk—but new research shows that this is true only in people with certain aortic shapes. Those with aortic arches that are less curved are more prone to stroke, according to a study published online Aug. 1 in Nature.